NEW YORK, Sept. 13, 2023 /PRNewswire/ — The contract cleaning services market size is to grow by USD 164.45 million from 2022 to 2027, at a CAGR of 6.92%. according to the latest research report from Technavio. The rising number of residential buildings is notably driving the market…

DUBLIN, Sept. 13, 2023 /PRNewswire/ — The “Singapore Social Commerce Market Intelligence and Future Growth Dynamics Databook – 50+ KPIs on Social Commerce Trends by End-Use Sectors, Operational KPIs, Retail Product Dynamics, and Consumer Demographics – Q2 2023 Update” report has been…

LUXEMBOURG, Sept. 13, 2023 /PRNewswire/ — Swiss Insured Brazil Power Finance S.à r.l., a private limited liability company (société à responsabilité limitée), incorporated and existing under Luxembourg law, having its registered office at 16, rue Eugène Ruppert, L – 2453 Luxembourg,…

DUBLIN, Sept. 13, 2023 /PRNewswire/ — The “Growth Opportunities in the Global Professional Headsets Market, Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering. The global professional headsets market was estimated to be $2.11 billion in 2022, decreasing by 6.7…

ASHFIELD, Angleterre, 14 septembre 2023 /PRNewswire/ — R&D Leverage Europe, une filiale d’Adler Industrial Solutions, a annoncé une expansion significative de ses services avec l’ajout des capacités de moulage par injection-soufflage (IBM). En 2023, la société a investi de manière…

DUBLIN, Sept. 13, 2023 /PRNewswire/ — The “Asia Pacific OTT TV and Video Forecasts 2023” report has been added to ResearchAndMarkets.com’s offering. Asia Pacific OTT TV episodes and movie revenues will reach $49 billion in 2029; up from the $34 billion recorded in 2023. This comes…

LAGUNA HILLS, Calif., Sept. 13, 2023 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the first ultra-low temperature cryoablation (ULTC) procedure performed using the…

SHANGHAI, 14 septembre 2023 /PRNewswire/ — Récemment, BioRay Pharmaceutical Co., Ltd. (ci-après dénommée « Bioray ») a annoncé que son produit biologique thérapeutique novateur de classe I, Zuberitamab Injection (nom commercial : Anruixi®), indiqué pour le traitement du lymphome diffus à…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.